Caffeine, CYPA12 and Resistance Exercise

NCT06610110 | Completed

• 1 other identifier: CEIP/2024/2/037
• Study Type: interventional
• Target: 60
• Locations: 1 country
• Sites: 2

Brief Summary

Introduction: Several studies have evaluated and confirmed the ergogenic effect of acute caffeine intake on sports performance, specifically on strength and power performance. However, it remains to be elucidated how CYP1A2 polymorphism influences the acute effects of caffeine on this type of exercise. Objectives: The present study aims to analyze the effects of acute caffeine intake on muscular strength, power, and endurance performance according to CYP1A2 polymorphism in men and women.

Conditions

CYP1A2 Polymorphism; Caffeine and Resistance Exercise

Outcome Measures

Primary Outcomes (10)

• cyp1a2 polymorphism

  Using saliva sample and PCR

  Before the beginning of the trial

• Mean velocity at different %1RM

  Measuring bar mean velocity desplacement during bench press and back squat exercises.

  Through study completion, an average of 2 weeks

• Peak velocity at different %1RM

  Measuring bar peak velocity and time to reach peak velocity of bar desplacement during bench press and back squat exercises.

  Through study completion, an average of 2 weeks

• Mean power output at different %1RM

  Measuring during bench press and back squat exercises.

  Through study completion, an average of 2 weeks

• Peak power output and time to reach peak power output at different %1RM

  Measuring during bench press and back squat exercises.

  Through study completion, an average of 2 weeks

• Number of repetitions performed in 1 set at 65%1RM until task failure

  In bench press and back squat exercises

  Through study completion, an average of 2 weeks

• Bar velocity deplacement performed in 1 set at 65%1RM until task failure

  In bench press and back squat exercises

  Through study completion, an average of 2 weeks

• Power output generated in 1 set at 65%1RM until task failure

  In bench press and back squat exercise

  Through study completion, an average of 2 weeks

• Maximal Fat Oxidation Rate (MFO)

  g/min (MFO) using a metabolic chart.

  Through study completion, an average of 2 weeks

• Resting Metabolic Rate (RMR)

  Kcal at rest (RMR) using a metabolic chart.

  Through study completion, an average of 2 weeks

Secondary Outcomes (5)

• Mood state (tension, depression, anger, vigor, fatigue and confusion)

  Through study completion, an average of 2 weeks

• Adverse effects

  Through study completion, an average of 2 weeks

• handgrip and isometric mid-thigh pull tests

  Through study completion, an average of 2 weeks

• Vertical Jump (cm)

  Through study completion, an average of 2 weeks

• Vertical Jump (power)

  Through study completion, an average of 2 weeks

Study Arms (8)

Genotype AA - Male - Caffeine

EXPERIMENTAL

Dietary Supplement: Caffeine

Genotype AC or CC - Male - Caffeine

EXPERIMENTAL

Dietary Supplement: Caffeine

Genotype AA - Male - Placebo

PLACEBO COMPARATOR

Dietary Supplement: Placebo

Genotype AC or CC - Male - Placebo

PLACEBO COMPARATOR

Dietary Supplement: Placebo

Genotype AA - Female - Caffeine

EXPERIMENTAL

Dietary Supplement: Caffeine

Genotype AC or CC - Female - Caffeine

EXPERIMENTAL

Dietary Supplement: Caffeine

Genotype AA - Female - Placebo

PLACEBO COMPARATOR

Dietary Supplement: Placebo

Genotype AC or CC - Female - Placebo

PLACEBO COMPARATOR

Dietary Supplement: Placebo

Interventions

Caffeine DIETARY_SUPPLEMENT

Acute caffeine intake (3 mg/kg)

Genotype AA - Female - Caffeine; Genotype AA - Male - Caffeine; Genotype AC or CC - Female - Caffeine; Genotype AC or CC - Male - Caffeine

Placebo DIETARY_SUPPLEMENT

Placebo (3 mg/kg maltodextrin)

Genotype AA - Female - Placebo; Genotype AA - Male - Placebo; Genotype AC or CC - Female - Placebo; Genotype AC or CC - Male - Placebo

Eligibility Criteria

• Age: 18 Years - 35 Years
• Sex: all
• Healthy Volunteers: Yes
• Age Groups: Adult (18-64)

You may qualify if:

• Age between ≥ 18 and ≤ 35 years.
• Body mass index (BMI) lower than 25 kg/m².
• Physically active subjects (≥150 min/week of moderate exercise).
• Healthy men and women without neurological, cardiometabolic, immunological, or physical conditions that prevent them from performing physical exercise.
• Participants capable of performing the tests.

You may not qualify if:

• History of neuromuscular, cardiac, or diseases that could affect liver or muscle metabolism.
• Use of drugs or other stimulants that interfere with caffeine intake and intestinal absorption during the tests and study.
• Body mass index (BMI) ≥ 25 kg/m².
• Having undergone prolonged periods of forced physical inactivity during the 6 months prior to the study.
• Performing strenuous exercise within 48 hours prior to the tests.
• Failing to replicate the same food intake on the two experimental days.
• Consuming caffeine after 6 PM on the day prior to training or testing.

Sponsors & Collaborators

• Alberto Pérez-López: lead
• University of Alcala: collaborator

Study Sites (2)

Facultad de Medicina y Ciencias de la Salud. Universidad de Alcalá

Alcalá de Henares, Madrid, 28805, Spain

Location

Facultad de Medicina y Ciencias de la Salud. Universidad de Alcalá

Alcalá de Henares, Madrid, Spain

Location

MeSH Terms

Interventions

Caffeine

Intervention Hierarchy (Ancestors)

Xanthines; Alkaloids; Heterocyclic Compounds; Purinones; Purines; Heterocyclic Compounds, 2-Ring; Heterocyclic Compounds, Fused-Ring

Study Design

• Study Type: interventional
• Phase: not applicable
• Allocation: RANDOMIZED
• Masking: DOUBLE
• Who Masked: PARTICIPANT, INVESTIGATOR
• Purpose: OTHER
• Intervention Model: CROSSOVER
• Sponsor Type: OTHER
• Responsible Party: SPONSOR INVESTIGATOR
• PI Title: Principal Investigator

Study Record Dates

• First Submitted: September 9, 2024
• First Posted: September 24, 2024
• Study Start: April 1, 2024
• Primary Completion: July 30, 2025
• Study Completion: July 30, 2025
• Last Updated: May 6, 2026

Record last verified: 2025-08

Data Sharing

• IPD Sharing: Will share

Locations

ES (2)